



COPY OF PAPERS  
ORIGINALLY FILED

1045

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Albrecht E. SIPPEL et al.

Serial No.: 09/869,595

Group Art Unit: 1645

AUG 15 2002

Filed: June 7, 2002

Examiner: Unassigned

TECH CENTER 160072900

For: METHOD FOR THE CELLULAR HIGH-THROUGHPUT-DETECTION OF NUCLEAR RECEPTOR LIGAND INTERACTIONS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents  
Washington, D. C. 20231

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed to:  
Assistant Commissioner For Patents,  
Washington, D.C. 20231 on August 6, 2002  
Name: JANICE EASLEY  
Signature: JANICE EASLEY  
Date: AUGUST 6, 2002

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_\_; see 37 C.F.R. § 1.98(d).
- ☒ Copies of materials listed but not attached were cited in an International Search Report dated May 9, 2000; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed June 28, 2002.

ADDITIONAL INFORMATION

COPY OF PAPERS  
ORIGINALLY FILED

LANGUAGE


- ☐ All listed materials are in the English language; see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
- ☐ The reference(s): \_\_\_\_\_ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): \_\_\_\_\_, respectively.
- ☐ (An) English-language translation(s) of the references: \_\_\_\_\_ is (are) provided.
- ☐ A commercial English-language abstract of reference(s) \_\_\_\_\_ is (are) provided.
- ☒ An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

## FEES

- ☒ No fee is required for this Information Disclosure Statement because:
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
  - ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
  - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
  - ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
- ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
  - ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

## CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.



DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$ \_\_\_\_\_. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

RECEIVED

AUG 15 2002

Respectfully submitted,

TECH CENTER 1600/2900

\_\_\_\_\_  
Anthony J. Zelano, Reg. No. 27,969  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

COPY OF PAPERS  
ORIGINALLY FILED

Attorney Docket No.: WEICKM-14

Date: August 6, 2002  
AJZ:jr

I hereby certify that this correspondence is being  
deposited with the U.S. Postal Services as First Class  
Mail in an envelope addressed to:  
Assistant Commissioner For Patents  
Washington, D.C. 20231-0001  
Name: Ignacio Rojas August 6, 2002  
Signature: [Signature]  
Date: August 6, 2002

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

AUG 15 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Please type a plus sign (+) inside this box → ☐

Institute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/869,595
Filing Date	June 7, 2002
First Named Inventor	Albrecht E. SIPPEL et al.
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	WEICKM-14

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Y. C. BRODER et al., "The RAS Recruitment System, A Novel Approach to the Study of Protein-Protein Interactions," CURRENT BIOLOGY, GB, CURRENT SCIENCE, Vol. 8, No. 20, pp. 1121-1124, October 1998, XP000867036.	
		A. ARONHEIM et al., "CHP, A Homologue of the GTPASE CDC42HS, Activates the JNK Pathway And is Implicated in Reorganizing the Actin Cytoskeleton," CURRENT BIOLOGY, GB, CURRENT SCIENCE, Vol. 8, No. 20, pp. 1125-1128-1128, October 1998, XP000867010.	
		A. ARONHEIM: "Improved Efficiency Sos Recruitment System: Expression of the Mammalian GAP Reduces Isolation of Ras GTPase False Positives," NUCLEIC ACIDS RESEARCH, Vol. 25, No. 16, pp 3373-3374, August 15, 1997, XP002136255	
		A. ARONHEIM et al., "Isolation of An AP-1 Repressor By A Novel Method for Detecting Protein-Protein Interactions," MOLECULAR AND CELLULAR BIOLOGY, US, AMERICAN SOCIETY FOR MICROBIOLOGY, Washington, Vol. 17, No. 6, pp. 3094-3102, June 1997, XP000867026	
		A. ARONHEIM et al., "Membrane Targeting of The Nucleotide Exchange Factor SOS is Sufficient for Activating the RAS Signaling Pathway," CELL, US, CELL PRESS, Cambridge, MA, Vol. 78, pp. 949-961, September 23, 1994, XP002037807.	
		J. SCHLESSINGER: "How Receptor Tyrosine Kinases Activate RAS," TRENDS IN BIOCHEMICAL SCIENCES, Vol. 18, No. 08, pp. 273-275, August 1993, XP002136256, Elsevier, Amsterdam, NL.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.